跳至主要内容
临床试验/NCT00084708
NCT00084708已完成1 期

A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors

Roswell Park Cancer Institute2 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2002年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
53
试验地点
2
主要终点
Maximum tolerated dose

研究概览

简要总结

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells. Dexamethasone may increase the effectiveness and decrease the side effects of gefitinib and calcitriol.

PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when given together with gefitinib or when given together with gefitinib and dexamethasone in treating patients with advanced solid tumors.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose (MTD), toxic effects, and tolerability of calcitriol alone and in combination with gefitinib with or without dexamethasone in patients with advanced solid tumors.

Secondary

  • Determine the pharmacokinetics and pharmacodynamics of these regimens in these patients.
  • Determine any tumor responses in patients treated with these regimens.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Maximum tolerated dose

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验